Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade

Behavioural Brain Research

Volumn 275, Issue , 2014, Pages 136-145

  Noseda, Ana Carolina D ^a   Rodrigues, Lais S ^a   Targa, Adriano D S ^a   Aurich, Mariana F ^a   Vital, Maria A B F ^a   Da Cunha, Cláudio ^a   Lima, Marcelo M S ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

4 P PDOT; 8 M PDOT; Dopamine; Parkinson's disease; Rotenone; Serotonin

Indexed keywords

4 PHENYL 2 PROPIONAMIDOTETRALIN; 8 METHOXY 2 PROPIONAMIDOTETRALIN; DOPAMINE; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR AGONIST; SEROTONIN; UNCLASSIFIED DRUG; 4-PHENYL-2-PROPIONAMIDOTETRALINE; 8-METHOXY-2-PROPIONAMIDOTETRALIN; BIOGENIC AMINE; INSECTICIDE; MELATONIN RECEPTOR; ROTENONE; TETRALIN DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FORCED SWIM TEST; HIPPOCAMPUS; MALE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; RAT; RECEPTOR BLOCKING; REM SLEEP DEPRIVATION; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; SLEEP DEPRIVATION; STATISTICS; SWIMMING; WISTAR RAT;

ANIMALS; BIOGENIC MONOAMINES; CORPUS STRIATUM; DEPRESSION; DISEASE MODELS, ANIMAL; INSECTICIDES; MALE; RATS; RATS, WISTAR; RECEPTORS, MELATONIN; ROTENONE; SLEEP DEPRIVATION; STATISTICS AS TOPIC; SWIMMING; TETRAHYDRONAPHTHALENES;

EID: 84907171514     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.09.007     Document Type: Article

References (57)

1. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339:1044-1053.
2. Lang A.E., Lozano A.M. Parkinson´s disease. Second of two parts. N Engl J Med 1998, 339:1130-1143.
3. Lima M.M., Martins E.F., Delattre A.M., Proenca M.B., Mori M.A., Carabelli B., et al. Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies. CNS Neurol Disord Drug Targets 2012, 11:439-449.
4. 3 H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988, 156:331-340.
5. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245.
6. Del Tredici K., Rub U., De Vos R.A., Bohl J.R., Braak H. Where does parkinson disease pathology begin in the brain. J Neuropathol Exp Neurol 2002, 61:413-426.
7. Prediger R.D., Matheus F.C., Schwarzbold M.L., Lima M.M., Vital M.A. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012, 62:115-124.
8. Santiago R.M., Barbieiro J., Lima M.M., Dombrowski P.A., Andreatini R., Vital M.A. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1104-1114.
9. Santiago R.M., Barbiero J., Gradowski R.W., Bochen S., Lima M.M., Da Cunha C., et al. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin. Behav Brain Res 2014, 259:70-77.
10. Dubocovich M.L. Melatonin receptors: are there multiple subtypes. Trends Pharmacol Sci 1995, 16:50-56.
11. Dubocovich M.L., Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27:101-110.
12. Carpentieri A., Diaz de Barboza G., Areco V., Peralta Lopez M., Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res 2012, 65:437-444.
13. Hardeland R. Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 2012, 3:194-225.
14. Hardeland R., Cardinali D.P., Srinivasan V., Spence D.W., Brown G.M., Pandi-Perumal S.R. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2011, 93:350-384.
15. Bordet R., Devos D., Brique S., Touitou Y., Guieu J.D., Libersa C., et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003, 26:65-72.
16. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 2001, 15:164-170.
17. Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther 2009, 15:345-357.
18. Capitelli C., Sereniki A., Lima M.M., Reksidler A.B., Tufik S., Vital M.A. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008, 594:101-108.
19. Sharma R., McMillan C.R., Tenn C.C., Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 2006, 1068:230-236.
20. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000, 275:31311-31317.
21. Jockers R., Maurice P., Boutin J.A., Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new. Br J Pharmacol 2008, 154:1182-1195.
22. Wu Y.H., Ursinus J., Zhou J.N., Scheer F.A., Ai-Min B., Jockers R., et al. Alterations of melatonin receptors MT1 and MT2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord 2013, 148:357-367.
23. Adi N., Mash D.C., Ali Y., Singer C., Shehadeh L., Papapetropoulos S. Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit 2010, 16:BR61-BR67.
24. Galecka E., Szemraj J., Florkowski A., Galecki P., Bienkiewicz M., Karbownik-Lewinska M., et al. Single nucleotide polymorphisms and mRNA expression for melatonin MT(2) receptor in depression. Psychiatry Res 2011, 189:472-474.
25. Zisapel N. Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 2001, 21:605-616.
26. Ochoa-Sanchez R., Rainer Q., Comai S., Spadoni G., Bedini A., Rivara S., et al. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:318-325.
27. Sumaya I.C., Masana M.I., Dubocovich M.L. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res 2005, 39:170-177.
28. Moreira C.G., Barbiero J.K., Ariza D., Dombrowski P.A., Sabioni P., Bortolanza M., et al. Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin. Neurotox Res 2012, 21:291-301.
29. Dos Santos A.C., Castro M.A., Jose E.A., Delattre A.M., Dombrowski P.A., Da Cunha C., et al. REM sleep deprivation generates cognitive and neurochemical disruptions in the intranigral rotenone model of Parkinson's disease. J Neurosci Res 2013, 91:1508-1516.
30. Machado R.B., Suchecki D., Tufik S. Comparison of the sleep pattern throughout a protocol of chronic sleep restriction induced by two methods of paradoxical sleep deprivation. Brain Res Bull 2006, 70:213-220.
31. Lima M.M.S., Andersen M.L., Reksidler A.B., Silva A., Zager A., Zanata S.M., et al. Blockage of dopaminergic D(2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 2008, 188:406-411.
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Academic Press, San Diego. 5th edition.
33. Saravanan K.S., Sindhu K.M., Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005, 1049:147-155.
34. Machado R.B., Hipolide D.C., Benedito-Silva A.A., Tufik S. Sleep deprivation induced by the modified multiple platform technique: quantification of sleep loss and recovery. Brain Res 2004, 1004:45-51.
35. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
36. Cryan J.F., Page M.E., Lucki I. Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 2002, 436:197-205.
37. Ergun Y., Orhan F.O., Karaaslan M.F. Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test. Eur J Pharmacol 2008, 591:159-163.
38. Ruksee N., Tongjaroenbuangam W., Mahanam T., Govitrapong P. Melatonin pretreatment prevented the effect of dexamethasone negative alterations on behavior and hippocampal neurogenesis in the mouse brain. J Steroid Biochem Mol Biol 2014, 143C:72-80.
39. Cotzias G.C., Tang L.C., Miller S.T., Ginos J.Z. Melatonin and abnormal movements induced by l-dopa in mice. Science 1971, 173:450-452.
40. Raghavendra V., Kaur G., Kulkarni S.K. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol 2000, 10:473-481.
41. Adrien J. Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 2002, 6:341-351.
42. Wirz-Justice A., Van den Hoofdakker R.H. Sleep deprivation in depression: what do we know, where do we go. Biol Psychiatry 1999, 46:445-453.
43. Landsness E.C., Goldstein M.R., Peterson M.J., Tononi G., Benca R.M. Antidepressant effects of selective slow wave sleep deprivation in major depression: a high-density EEG investigation. J Psychiatr Res 2011, 45:1019-1026.
44. Southmayd S.E., David M.M., Cairns J., Delva N.J., Letemendia F.J., Waldron J.J. Sleep deprivation in depression: pattern of relapse and characteristics of preceding sleep. Biol Psychiatry 1990, 28:979-988.
45. Mineur Y.S., Obayemi A., Wigestrand M.B., Fote G.M., Calarco C.A., Li A.M., et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci USA 2013, 110:3573-3578.
46. Gillin J.C., Sutton L., Ruiz C., Kelsoe J., Dupont R.M., Darko D., et al. The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry 1991, 48:264-270.
47. Maturana M.J., Pudell C., Targa A.D., Rodrigues L.S., Noseda A.C., Fortes M.H., et al. REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy. Mol Neurobiol 2014, in press.
48. Schrag A. Psychiatric aspects of Parkinson's disease-an update. J Neurol 2004, 251:795-804.
49. Dremencov E., Newman M.E., Kinor N., Blatman-Jan G., Schindler C.J., Overstreet D.H., et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005, 48:34-42.
50. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000, 62:63-88.
51. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., Monteggia L.M. Neurobiology of depression. Neuron 2002, 34:13-25.
52. Dubocovich M.L., Masana M.I., Iacob S., Sauri D.M. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 1997, 355:365-375.
53. Browning C., Beresford I., Fraser N., Giles H. Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 2000, 129:877-886.
54. Comai S., Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2014, 39:6-21.
55. Fisher S.P., Sugden D. Sleep-promoting action of IIK7, a selective MT2 melatonin receptor agonist in the rat. Neurosci Lett 2009, 457:93-96.
56. Vogel G.W. Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs. Prog Neuropsychopharmacol Biol Psychiatry 1983, 7:343-349.
57. Wang Y.Q., Tu Z.C., Xu X.Y., Li R., Qu W.M., Urade Y., et al. Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats. J Neurochem 2012, 120:314-324.